Your health and safety remain our top priority: Learn about our Safe Care Commitment | Use our Prescreen app before arrival for faster entry | Read the COVID-19 Vaccine FAQs
If you are interested in learning more about our clinical trials, please fill out your information at the following link:
Alzheimer Research Online Survey Form
At Brigham and Women's Center for Alzheimer Research and Treatment (CART), we conduct two major types of clinical research studies: Observational or natural history studies and Interventional or therapeutic clinical trials. In observational studies, participants undergo memory and thinking tests as well as brain imaging scans. Researchers at CART are working on developing more sensitive cognitive tests, biomarkers and neuroimaging techniques like MRI and PET scans to detect early brain changes related to Alzheimer’s disease (AD), and to differentiate these changes from “normal aging”.
In the therapeutic clinical trials, participants receive an experimental drug or a placebo to test new potential therapies to treat Alzheimer’s disease. CART is currently enrolling participants in multiple studies, including studies for older individuals with normal cognition, subjects with mild cognitive impairment (MCI), and patients who have been diagnosed with mild Alzheimer’s disease dementia. Please see information about individual studies below.
Our center is currently conducting clinical trials of treatments for people with mild-to-moderate Alzheimer's disease and mild cognitive impairment. Participants in clinical trials may benefit from the added monitoring, support, and information received during the trial, but it is important to understand both the potential risk and benefits of participation before enrolling. For general information about clinical trials, including a list of questions to ask when considering a trial, please see our resources section or call us at 617-732-8085. For specific information about trials, including eligibility requirements, please see the individual trial listings below.
This study will assess the safety, tolerability and effectiveness of a new investigational medication to determine if it will halt or reduce the spread of tau (a protein that makes up neurofibrillary tangles in the brain) and see if it will stop or slow the progression of symptoms in individuals living with mild-to-moderate Alzheimer’s disease (AD). There are currently no approved disease modifying agents for individuals living with mild-to-moderate AD so it is important to find a treatment that could prevent further brain changes. Please consider enrolling in this study.
This study is assessing the dose levels, safety, tolerability and effectiveness of a new investigational medication (MTAU9937A, a monoclonal antibody- passive vaccine- that may halt or reduce the spread of tau in the brain) to determine whether it can stop or slow the progression of symptoms in individuals living with mild-to-moderate AD.
This research study (also known as a clinical trial) is of an investigational drug called gantenerumab. If you have Alzheimer’s disease (AD) or may have early symptoms of AD, you may be eligible for this study. AD is a slow progressive disease of the brain that affects memory and other normal brain functions. The brains of individuals with AD have an abundance of plaques and tangles. Plaques are deposits of a protein called amyloid; tangles are twisted fibers of another protein called tau. More information…
The Tango Study is evaluating the safety, dosing, and effectiveness of an investigational medication designed to target the tau protein, which is one of the key proteins that builds up in the brain and contributes to cognitive decline. More information…
The Aware Study assesses the effectiveness and safety of an investigational medication (monoclonal antibody - passive vaccine - that removes abnormal Tau protein from the brain) to determine whether it can reduce symptoms in early AD. The sponsor of the Aware Study is AbbVie pharmaceutical company. More information...
The purpose of this study is to compare the effects, good or bad, of MTAU9937A versus placebo (an inactive substance that looks like MTAU9937A) on you and your Alzheimer’s disease to find out which is better. MTAU9937A is an antibody, a special molecule in the blood and tissue that can attach to other molecules. MTAU9937A is being studied for the treatment of Alzheimer’s disease. More information…
Want to help us improve our understanding of how Alzheimer's disease develops and progresses? The ADNI-3 study will create a national database of brain aging to improve clinical trials and provide researchers across the country with data to study how quickly brain cognition and function changes. The study is funded by the NIH. More information…
The Trial Ready Cohort (TRC) study is to build a large group, or “cohort”, of individuals who are interested in being recruited into clinical trials aimed at reducing the risk of developing AD dementia. To do this, we will collect data from cognitively normal or minimally impaired individuals and then inform them if a trial may be appropriate for them. New treatments that may help prevent or slow the symptoms of Alzheimer’s disease (AD) are urgently needed and you can help find the next breakthrough medication. Our goal with the Trial Ready Cohort (TRC) project is to build a large group, or “cohort”, of individuals who are interested in being recruited into clinical trials aimed at reducing the risk of developing AD dementia.
Join the APT Web Study
Are you interested in volunteering for Alzheimer’s prevention research? The APT Webstudy is an online memory and thinking research tool aimed at accelerating enrollment into Alzheimer’s clinical trials, by identifying and tracking individuals who may be at higher risk for developing Alzheimer’s. If you are age 50+, interested in being part of Alzheimer’s prevention trials and want to learn more, please visit www.aptwebstudy.org.
We are inspired by our patients' courage, our caregivers' compassion, and our scientists' curiosity - all fueled by our donors' generosity.
Imagine what we can do together.